To maintain a vaccine center with broad capabilities to evaluate prophylactic and therapeutic agents against human pathogens other than AIDS. To evaluate vaccine candidates in a critical and objective fashion for safety, immunogenicity, transmissibility, stability and efficacy, we will put a special emphasis on comparative trials of different vaccines against a common agent. To study the biology of microbial agents targeted for vaccine development in order to enhance understanding of attenuation and virulence mechanisms. To examine in detail the host response in man and animal systems to a particular vaccine in so far as it will help understand the mechanism(s) of protective efficacy of the vaccine in question and/or the basic pathogenesis of the disease for which prevention is sought. To contribute to the direction and focus that vaccine development should pursue at a national and international level.

Project Start
1989-10-08
Project End
1994-10-07
Budget Start
1991-10-25
Budget End
1992-10-07
Support Year
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Pediatrics
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Tai, Jennifer H; Williams, John V; Edwards, Kathryn M et al. (2005) Prevalence of reovirus-specific antibodies in young children in Nashville, Tennessee. J Infect Dis 191:1221-4
Neuzil, Kathleen M; Zhu, Yuwei; Griffin, Marie R et al. (2002) Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. J Infect Dis 185:147-52
Gruber, W C; Darden, P M; Still, J G et al. (1997) Evaluation of bivalent live attenuated influenza A vaccines in children 2 months to 3 years of age: safety, immunogenicity and dose-response. Vaccine 15:1379-84
Fisher, R G; Gruber, W C; Edwards, K M et al. (1997) Twenty years of outpatient respiratory syncytial virus infection: a framework for vaccine efficacy trials. Pediatrics 99:E7
Neuzil, K M; Tang, Y W; Graham, B S (1996) Protective Role of TNF-alpha in respiratory syncytial virus infection in vitro and in vivo. Am J Med Sci 311:201-4
Endo, Y; Carroll, K N; Ikizler, M R et al. (1996) Growth of influenza A virus in primary, differentiated epithelial cells derived from adenoids. J Virol 70:2055-8
Tang, Y W; Graham, B S (1994) Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus. J Clin Invest 94:1953-8
Graham, B S; Davis, T H; Tang, Y W et al. (1993) Immunoprophylaxis and immunotherapy of respiratory syncytial virus-infected mice with respiratory syncytial virus-specific immune serum. Pediatr Res 34:167-72
Graham, B S; Henderson, G S; Tang, Y W et al. (1993) Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol 151:2032-40